JP2016516026A - Ｒｅａｒｒａｎｇｅｄｄｕｒｉｎｇｔｒａｎｓｆｅｃｔｉｏｎ（ｒｅｔ）キナーゼ阻害剤としてのピリジン誘導体 - Google Patents
Ｒｅａｒｒａｎｇｅｄｄｕｒｉｎｇｔｒａｎｓｆｅｃｔｉｏｎ（ｒｅｔ）キナーゼ阻害剤としてのピリジン誘導体 Download PDFInfo
- Publication number
- JP2016516026A JP2016516026A JP2015562529A JP2015562529A JP2016516026A JP 2016516026 A JP2016516026 A JP 2016516026A JP 2015562529 A JP2015562529 A JP 2015562529A JP 2015562529 A JP2015562529 A JP 2015562529A JP 2016516026 A JP2016516026 A JP 2016516026A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- ethoxy
- fluorophenyl
- acetamide
- trifluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(*)(C=C(CC(N*)=O)C=C1)C=C1C(C=N1)=CI(C)C=C1OP Chemical compound CC(*)(C=C(CC(N*)=O)C=C1)C=C1C(C=N1)=CI(C)C=C1OP 0.000 description 6
- GJSFSDMLTLWFQN-UHFFFAOYSA-N COC(Cc(cc1F)ccc1Br)=O Chemical compound COC(Cc(cc1F)ccc1Br)=O GJSFSDMLTLWFQN-UHFFFAOYSA-N 0.000 description 2
- CUCGKHLLFAWHAD-UHFFFAOYSA-N CC(C)(C(F)(F)F)C(NC=C1)=CC1=O Chemical compound CC(C)(C(F)(F)F)C(NC=C1)=CC1=O CUCGKHLLFAWHAD-UHFFFAOYSA-N 0.000 description 1
- ACTSELRTDUHDQG-UHFFFAOYSA-N CC(C)(C(F)(F)F)c1n[o]c(NC(Cc(ccc(Br)c2)c2F)=O)c1 Chemical compound CC(C)(C(F)(F)F)c1n[o]c(NC(Cc(ccc(Br)c2)c2F)=O)c1 ACTSELRTDUHDQG-UHFFFAOYSA-N 0.000 description 1
- UHJAKEYPNYDFBC-UHFFFAOYSA-N CC1(C)OS(c(cc2)cnc2OP)OC1(C)C Chemical compound CC1(C)OS(c(cc2)cnc2OP)OC1(C)C UHJAKEYPNYDFBC-UHFFFAOYSA-N 0.000 description 1
- VDGHPSLOOLHULM-UHFFFAOYSA-N CCN1CCN(Cc(cc2)c(C(F)(F)F)cc2NC(Cc(c(F)c2)ccc2C(C=C2OCC)=CNC2=O)=O)CC1 Chemical compound CCN1CCN(Cc(cc2)c(C(F)(F)F)cc2NC(Cc(c(F)c2)ccc2C(C=C2OCC)=CNC2=O)=O)CC1 VDGHPSLOOLHULM-UHFFFAOYSA-N 0.000 description 1
- JUVBSNZZSZUVKT-UHFFFAOYSA-N CCOC(C(C)(C)Cc(c(C(F)(F)F)c1)ccc1N)=O Chemical compound CCOC(C(C)(C)Cc(c(C(F)(F)F)c1)ccc1N)=O JUVBSNZZSZUVKT-UHFFFAOYSA-N 0.000 description 1
- FNTTVDWBQNXKNH-UHFFFAOYSA-N CCOC(C(C)(C)Cc(c(C(F)(F)F)c1)ccc1NC(Cc(c(F)c1)ccc1Br)=O)=O Chemical compound CCOC(C(C)(C)Cc(c(C(F)(F)F)c1)ccc1NC(Cc(c(F)c1)ccc1Br)=O)=O FNTTVDWBQNXKNH-UHFFFAOYSA-N 0.000 description 1
- KPZIPXQEQUVBPR-UHFFFAOYSA-N CCOC(C(C)(C)Cc(c(C(F)(F)F)c1)ccc1NC(Cc(ccc(S1OC(C)(C)C(C)(C)O1)c1)c1F)=O)=O Chemical compound CCOC(C(C)(C)Cc(c(C(F)(F)F)c1)ccc1NC(Cc(ccc(S1OC(C)(C)C(C)(C)O1)c1)c1F)=O)=O KPZIPXQEQUVBPR-UHFFFAOYSA-N 0.000 description 1
- CWNJPRHRUJJDFY-UHFFFAOYSA-N CCOC(C(C)(C)Cc(c(C(F)(F)F)c1)ccc1[N+]([O-])=O)=O Chemical compound CCOC(C(C)(C)Cc(c(C(F)(F)F)c1)ccc1[N+]([O-])=O)=O CWNJPRHRUJJDFY-UHFFFAOYSA-N 0.000 description 1
- FYJMXDYOAPYOGN-UHFFFAOYSA-N CCOC(C(c1cc(F)c(CC(Nc(cc2C(F)(F)F)ccc2OCCO)=O)cc1)=CN1)=CC1=O Chemical compound CCOC(C(c1cc(F)c(CC(Nc(cc2C(F)(F)F)ccc2OCCO)=O)cc1)=CN1)=CC1=O FYJMXDYOAPYOGN-UHFFFAOYSA-N 0.000 description 1
- CMGWPZPIBTZFRI-UHFFFAOYSA-N CCOC(C(c1cc(F)c(CC(Nc2cccc(C(F)(F)F)c2)=O)cc1)=CN1)=CC1=O Chemical compound CCOC(C(c1cc(F)c(CC(Nc2cccc(C(F)(F)F)c2)=O)cc1)=CN1)=CC1=O CMGWPZPIBTZFRI-UHFFFAOYSA-N 0.000 description 1
- JORMEFORQOPPLC-UHFFFAOYSA-N CCOC(C(c1ccc(CC(O)=O)c(F)c1)=CN1)=CC1=O Chemical compound CCOC(C(c1ccc(CC(O)=O)c(F)c1)=CN1)=CC1=O JORMEFORQOPPLC-UHFFFAOYSA-N 0.000 description 1
- YSJLEKLBWVIFQS-UHFFFAOYSA-N CCOC1=CC(c2cc(F)c(CC(Nc3cnc(C(C)C#N)c(C(F)(F)F)c3)=O)cc2)=CNC1=O Chemical compound CCOC1=CC(c2cc(F)c(CC(Nc3cnc(C(C)C#N)c(C(F)(F)F)c3)=O)cc2)=CNC1=O YSJLEKLBWVIFQS-UHFFFAOYSA-N 0.000 description 1
- XRGNPERDXDHTOQ-KLGMHCSDSA-N CCOC1=CC(c2ccc(CC(N/C(/N)=C/C(C(C)(C)C(F)(F)F)=N)=O)c(F)c2)=CNC1=O Chemical compound CCOC1=CC(c2ccc(CC(N/C(/N)=C/C(C(C)(C)C(F)(F)F)=N)=O)c(F)c2)=CNC1=O XRGNPERDXDHTOQ-KLGMHCSDSA-N 0.000 description 1
- UHEIXBWQHRWKCW-UHFFFAOYSA-N CCOC1=CC(c2ccc(CC(Nc(cc3Cl)ccc3Cl)=O)c(F)c2)=CNC1=O Chemical compound CCOC1=CC(c2ccc(CC(Nc(cc3Cl)ccc3Cl)=O)c(F)c2)=CNC1=O UHEIXBWQHRWKCW-UHFFFAOYSA-N 0.000 description 1
- MUPXUGCDYKLAGU-UHFFFAOYSA-N CCOc(c(C(F)(F)F)c1)ncc1NC(Cc(c(F)c1)ccc1Br)=O Chemical compound CCOc(c(C(F)(F)F)c1)ncc1NC(Cc(c(F)c1)ccc1Br)=O MUPXUGCDYKLAGU-UHFFFAOYSA-N 0.000 description 1
- KRQMXUKTITUPGP-UHFFFAOYSA-N CCOc1cc(OCc2ccccc2)ncc1-c1cc(F)c(CC(Nc2ccc(CC(C)(C)CO)c(C(F)(F)F)c2)=O)cc1 Chemical compound CCOc1cc(OCc2ccccc2)ncc1-c1cc(F)c(CC(Nc2ccc(CC(C)(C)CO)c(C(F)(F)F)c2)=O)cc1 KRQMXUKTITUPGP-UHFFFAOYSA-N 0.000 description 1
- DTCYXLYLYMJZCR-UHFFFAOYSA-N CCOc1cc(OCc2ccccc2)ncc1I Chemical compound CCOc1cc(OCc2ccccc2)ncc1I DTCYXLYLYMJZCR-UHFFFAOYSA-N 0.000 description 1
- CQCXXBSMLPMFOU-UHFFFAOYSA-N Cc(cc1)n[n]1-c1cc(C(F)(F)F)cc(N)c1 Chemical compound Cc(cc1)n[n]1-c1cc(C(F)(F)F)cc(N)c1 CQCXXBSMLPMFOU-UHFFFAOYSA-N 0.000 description 1
- JHLCLALPGFWTGY-UHFFFAOYSA-N N#CCc(c(C(F)(F)F)c1)ncc1[N+]([O-])=O Chemical compound N#CCc(c(C(F)(F)F)c1)ncc1[N+]([O-])=O JHLCLALPGFWTGY-UHFFFAOYSA-N 0.000 description 1
- FSQINZQIPFZWKX-UHFFFAOYSA-N N#Cc1cc(C(F)(F)F)cc([N+]([O-])=O)c1 Chemical compound N#Cc1cc(C(F)(F)F)cc([N+]([O-])=O)c1 FSQINZQIPFZWKX-UHFFFAOYSA-N 0.000 description 1
- IVMMVWKAROMENU-UHFFFAOYSA-N NC(c1cc([N+]([O-])=O)cc(C(F)(F)F)c1)=O Chemical compound NC(c1cc([N+]([O-])=O)cc(C(F)(F)F)c1)=O IVMMVWKAROMENU-UHFFFAOYSA-N 0.000 description 1
- LSRHFWSNUFIKER-UHFFFAOYSA-N OCc(c(F)cc(Br)c1)c1F Chemical compound OCc(c(F)cc(Br)c1)c1F LSRHFWSNUFIKER-UHFFFAOYSA-N 0.000 description 1
- OPEZLLCPUDLUFV-UHFFFAOYSA-N [O-][N+](c(cc1C(F)(F)F)cnc1Cl)=O Chemical compound [O-][N+](c(cc1C(F)(F)F)cnc1Cl)=O OPEZLLCPUDLUFV-UHFFFAOYSA-N 0.000 description 1
- DQAMZQPGZDUURQ-UHFFFAOYSA-N [O-][N+](c1cc(C(F)(F)F)cc(OCCN2CCOCC2)c1)=O Chemical compound [O-][N+](c1cc(C(F)(F)F)cc(OCCN2CCOCC2)c1)=O DQAMZQPGZDUURQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2013/072683 | 2013-03-15 | ||
| CN2013072683 | 2013-03-15 | ||
| CNPCT/CN2013/090059 | 2013-12-20 | ||
| CN2013090059 | 2013-12-20 | ||
| CNPCT/CN2014/072449 | 2014-02-24 | ||
| CN2014072449 | 2014-02-24 | ||
| PCT/IB2014/059817 WO2014141187A1 (en) | 2013-03-15 | 2014-03-14 | Pyridine derivatives as rearranged during transfection (ret) kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016516026A true JP2016516026A (ja) | 2016-06-02 |
| JP2016516026A5 JP2016516026A5 (enExample) | 2017-04-13 |
Family
ID=50390154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562529A Pending JP2016516026A (ja) | 2013-03-15 | 2014-03-14 | Ｒｅａｒｒａｎｇｅｄｄｕｒｉｎｇｔｒａｎｓｆｅｃｔｉｏｎ（ｒｅｔ）キナーゼ阻害剤としてのピリジン誘導体 |
Country Status (33)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023512546A (ja) * | 2020-02-20 | 2023-03-27 | 広州白雲山医薬集団股▲フン▼有限公司白雲山制薬総廠 | キノリン系化合物 |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011256380C1 (en) | 2010-05-20 | 2016-09-08 | Array Biopharma Inc. | Macrocyclic compounds as Trk kinase inhibitors |
| CN107148418A (zh) * | 2014-09-08 | 2017-09-08 | 葛兰素史密斯克莱知识产权发展有限公司 | 2‑(4‑(4‑乙氧基‑6‑氧代‑1,6‑二氢吡啶‑3‑基)‑2‑氟苯基)‑n‑(5‑(1,1,1‑三氟‑2‑甲基丙‑2‑基)异噁唑‑3‑基)乙酰胺的晶型 |
| RS58813B1 (sr) | 2014-09-10 | 2019-07-31 | Glaxosmithkline Ip Dev Ltd | Piridonski derivati korišćeni kao inhibitori kinaze reorganizovane tokom transfekcije (ret) |
| JP6538153B2 (ja) | 2014-09-10 | 2019-07-03 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｒｅａｒｒａｎｇｅｄ ｄｕｒｉｎｇ ｔｒａｎｓｆｅｃｔｉｏｎ（ｒｅｔ）阻害剤としての新規な化合物 |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| JP6816100B2 (ja) | 2015-07-16 | 2021-01-20 | アレイ バイオファーマ、インコーポレイテッド | ＲＥＴキナーゼ阻害物質としての置換ピラゾロ［１，５−ａ］ピリジン化合物 |
| WO2017019804A2 (en) | 2015-07-28 | 2017-02-02 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| TWI787018B (zh) | 2015-11-02 | 2022-12-11 | 美商纜圖藥品公司 | 轉染過程重排之抑制劑 |
| WO2017145050A1 (en) | 2016-02-23 | 2017-08-31 | Glaxosmithkline Intellectual Property Development Limited | Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer |
| JP6921846B6 (ja) * | 2016-03-16 | 2021-09-15 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | キナーゼ調節およびその適応症のための化合物および方法 |
| UY37155A (es) | 2016-03-17 | 2017-10-31 | Blueprint Medicines Corp | Inhibidores de ret |
| AU2017263174A1 (en) | 2016-05-13 | 2018-12-13 | Instituto de Medicina Molecular João Lobo Antunes | Methods of treating diseases associated with ILC3 cells |
| US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| JP2018052878A (ja) | 2016-09-29 | 2018-04-05 | 第一三共株式会社 | ピリジン化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| ES2948194T3 (es) | 2017-01-18 | 2023-09-01 | Array Biopharma Inc | Compuestos de pirazolo[1,5-a]pirazina sustituida como inhibidores de la cinasa RET |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| EP3624802A1 (en) | 2017-05-15 | 2020-03-25 | Blueprint Medicines Corporation | Combinations of ret inhibitors and mtorc1 inhibitors and uses thereof for the treatment of cancer mediated by aberrant ret activity |
| US10093648B1 (en) * | 2017-09-22 | 2018-10-09 | Celgene Corporation | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof |
| TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| US11603374B2 (en) | 2018-01-18 | 2023-03-14 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| TW201938169A (zh) | 2018-01-18 | 2019-10-01 | 美商亞雷生物製藥股份有限公司 | 作為RET激酶抑制劑之經取代吡唑并[3,4-d]嘧啶化合物 |
| JP6997876B2 (ja) | 2018-01-18 | 2022-02-04 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物 |
| CA3096043A1 (en) | 2018-04-03 | 2019-10-10 | Blueprint Medicines Corporation | Ret inhibitor for use in treating cancer having a ret alteration |
| CN109096264B (zh) * | 2018-08-28 | 2019-08-23 | 山东理工职业学院 | Ret抑制剂及其制备方法、组合物和用途 |
| CA3111984A1 (en) | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
| US20230086702A1 (en) | 2019-04-18 | 2023-03-23 | The Johns Hopkins University | Substituted 2-amino-pyrazolyl-[1,2,4]triazolo[1,5a]pyridine derivatives and use thereof |
| TWI777509B (zh) * | 2020-04-27 | 2022-09-11 | 美商美國禮來大藥廠 | 用於抑制ret激酶之化合物 |
| CA3183728A1 (en) | 2020-05-29 | 2021-12-02 | Blueprint Medicines Corporation | Solid forms of pralsetinib |
| TWI786742B (zh) * | 2020-07-23 | 2022-12-11 | 大陸商深圳晶泰科技有限公司 | 吡啶酮類化合物及其製備方法和應用 |
| US11697647B2 (en) * | 2020-11-06 | 2023-07-11 | Eli Lilly And Company | RET kinase inhibitors |
| IL309027A (en) | 2021-06-03 | 2024-02-01 | Fundac?O D Anna De Sommer Champalimaud E Dr Carlos Montez Champalimaud | Neuro-messenger units that control ILC2 and obesity in brain fat cell circuit findings |
| CN115626880B (zh) * | 2022-11-15 | 2023-11-14 | 常州大学 | 3-硝基-5-氰基三氟甲苯的合成方法 |
| CN116925023B (zh) * | 2023-07-18 | 2025-11-21 | 江苏桐孚高新材料有限公司 | 2-全氟烷基-4h-吡喃-4-酮衍生物的改进合成方法 |
| EP4650002A1 (en) * | 2024-05-15 | 2025-11-19 | Ludwig-Maximilians-Universität | Aniline-based modulators of the nuclear receptor tlx (nr2e1) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004517840A (ja) * | 2000-11-27 | 2004-06-17 | フアルマシア・イタリア・エツセ・ピー・アー | フェニルアセトアミド−ピラゾール誘導体およびそれの抗腫瘍薬としての使用 |
| JP2010506879A (ja) * | 2006-10-16 | 2010-03-04 | ノバルティス アーゲー | プロテインキナーゼ阻害剤として有用なフェニルアセトアミド |
| JP2010509375A (ja) * | 2006-11-15 | 2010-03-25 | サイトピア・リサーチ・ピーティーワイ・リミテッド | キナーゼ活性の阻害剤 |
| JP2013502429A (ja) * | 2009-08-19 | 2013-01-24 | アムビト ビオスシエンセス コルポラチオン | ビアリール化合物及びその使用方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0013143A (pt) | 1999-08-12 | 2002-06-11 | Pharmacia Italia Spa | Derivados de 3 (5) amino pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais |
| DE10201764A1 (de) | 2002-01-18 | 2003-07-31 | Bayer Cropscience Ag | Substituierte 4-Aminopyridin-Derivate |
| US7968574B2 (en) | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
| WO2012082817A1 (en) | 2010-12-16 | 2012-06-21 | Boehringer Ingelheim International Gmbh | Biarylamide inhibitors of leukotriene production |
| US8937071B2 (en) | 2013-03-15 | 2015-01-20 | Glaxosmithkline Intellectual Property Development Limited | Compounds as rearranged during transfection (RET) inhibitors |
-
2014
- 2014-03-14 UA UAA201510041A patent/UA115264C2/uk unknown
- 2014-03-14 ES ES14713598.2T patent/ES2616655T3/es active Active
- 2014-03-14 HU HUE14713598A patent/HUE033423T2/en unknown
- 2014-03-14 PE PE2015001878A patent/PE20151538A1/es not_active Application Discontinuation
- 2014-03-14 BR BR112015023618A patent/BR112015023618A2/pt not_active IP Right Cessation
- 2014-03-14 TW TW103109315A patent/TW201524958A/zh unknown
- 2014-03-14 UY UY0001035465A patent/UY35465A/es unknown
- 2014-03-14 JP JP2015562529A patent/JP2016516026A/ja active Pending
- 2014-03-14 WO PCT/IB2014/059817 patent/WO2014141187A1/en not_active Ceased
- 2014-03-14 DK DK14713598.2T patent/DK2970191T3/en active
- 2014-03-14 ME MEP-2017-60A patent/ME02664B/me unknown
- 2014-03-14 PL PL14713598T patent/PL2970191T3/pl unknown
- 2014-03-14 LT LTEP14713598.2T patent/LT2970191T/lt unknown
- 2014-03-14 CN CN201480015907.3A patent/CN105051027A/zh active Pending
- 2014-03-14 CA CA2905627A patent/CA2905627A1/en not_active Abandoned
- 2014-03-14 EP EP14713598.2A patent/EP2970191B1/en active Active
- 2014-03-14 RS RS20170177A patent/RS55710B1/sr unknown
- 2014-03-14 NZ NZ628388A patent/NZ628388A/en not_active IP Right Cessation
- 2014-03-14 SG SG11201506695UA patent/SG11201506695UA/en unknown
- 2014-03-14 EA EA201591738A patent/EA029296B1/ru not_active IP Right Cessation
- 2014-03-14 SI SI201430170A patent/SI2970191T1/sl unknown
- 2014-03-14 HR HRP20170363TT patent/HRP20170363T1/hr unknown
- 2014-03-14 AU AU2014229233A patent/AU2014229233B2/en not_active Ceased
- 2014-03-14 US US14/775,772 patent/US9382238B2/en not_active Expired - Fee Related
- 2014-03-14 SM SM20170152T patent/SMT201700152T1/it unknown
- 2014-03-14 MX MX2015012286A patent/MX2015012286A/es unknown
- 2014-03-14 PT PT147135982T patent/PT2970191T/pt unknown
-
2015
- 2015-09-03 IL IL241161A patent/IL241161A0/en unknown
- 2015-09-08 CL CL2015002514A patent/CL2015002514A1/es unknown
- 2015-09-10 PH PH12015502044A patent/PH12015502044A1/en unknown
- 2015-09-14 CR CR20150490A patent/CR20150490A/es unknown
- 2015-09-15 DO DO2015000244A patent/DOP2015000244A/es unknown
-
2016
- 2016-06-02 US US15/171,229 patent/US9789100B2/en not_active Expired - Fee Related
-
2017
- 2017-03-14 CY CY20171100319T patent/CY1118730T1/el unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004517840A (ja) * | 2000-11-27 | 2004-06-17 | フアルマシア・イタリア・エツセ・ピー・アー | フェニルアセトアミド−ピラゾール誘導体およびそれの抗腫瘍薬としての使用 |
| JP2010506879A (ja) * | 2006-10-16 | 2010-03-04 | ノバルティス アーゲー | プロテインキナーゼ阻害剤として有用なフェニルアセトアミド |
| JP2010509375A (ja) * | 2006-11-15 | 2010-03-25 | サイトピア・リサーチ・ピーティーワイ・リミテッド | キナーゼ活性の阻害剤 |
| JP2013502429A (ja) * | 2009-08-19 | 2013-01-24 | アムビト ビオスシエンセス コルポラチオン | ビアリール化合物及びその使用方法 |
Non-Patent Citations (1)
| Title |
|---|
| BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 20, no. 16, JPN6018002505, 2010, pages 4819 - 4824, ISSN: 0003728082 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023512546A (ja) * | 2020-02-20 | 2023-03-27 | 広州白雲山医薬集団股▲フン▼有限公司白雲山制薬総廠 | キノリン系化合物 |
| JP7461605B2 (ja) | 2020-02-20 | 2024-04-04 | 広州白雲山医薬集団股▲フン▼有限公司白雲山制薬総廠 | キノリン系化合物 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9789100B2 (en) | Compounds as rearranged during transfection (RET) inhibitors | |
| US9035063B2 (en) | Compounds as rearranged during transfection (RET) inhibitors | |
| US10294236B2 (en) | Compounds as rearranged during transfection (RET) inhibitors | |
| JP6728447B2 (ja) | Ｒｅｔ（ｒｅａｒｒａｎｇｅｄ ｄｕｒｉｎｇ ｔｒａｎｓｆｅｃｔｉｏｎ）キナーゼ阻害剤としてのピリジン誘導体 | |
| KR20150130464A (ko) | 형질감염 중 재배열 (ret) 키나제 억제제로서의 피리딘 유도체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20170106 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170310 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170310 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180125 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180130 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180828 |